title: Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily.
abstract: BACKGROUND
  The purpose of this study was to evaluate the safety and efficacy of a fixed combination of timolol maleate 0.5% + brimonidine tartrate 0.2% (Combigan®) for reduction for intraocular pressure (IOP) in patients with glaucoma when the dose frequency is increased from twice to three times daily.
  
  
  METHODS
  The patients included had either primary open angle glaucoma or ocular hypertension. Those who were previously on treatment completed a drug washout period prior to inclusion. IOP was measured at baseline, after 4 weeks of treatment with Combigan twice daily, and again after a further 4 weeks of Combigan three times daily. Blood pressure, heart rate, and oxygen saturation were also recorded at each assessment.
  
  
  RESULTS
  Thirty-one eyes from 31 patients were included. Increasing the Combigan dose frequency resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.25 ± 1.18 mmHg, corresponding to a further 10.3% reduction in IOP from baseline. No local or systemic adverse effects were documented.
  
  
  CONCLUSIONS
  Treatment with Combigan three times daily was more effective in reducing IOP than the twice-daily regimen, with no increase in adverse effects.
authors.affiliation: Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
authors.forename: Elad
authors.initials: E
authors.lastname: Moisseiev
authors.forename: Shimon
authors.initials: S
authors.lastname: Kurtz
authors.forename: Moshe
authors.initials: M
authors.lastname: Lazar
authors.forename: Gabi
authors.initials: G
authors.lastname: Shemesh
keywords: Combigan®; brimonidine; dose frequency; glaucoma; timolol